Full Press Release Details
University of British Columbia to Perform Clinical Study on
the Cardiovascular and
Cognitive Health Effects of Lexaria s
Kelowna, British Columbia August 31, 2017 Lexaria
Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the Company or Lexaria ) announces
the world s first clinical study on human volunteers of cannabindiol (CBD)
within Lexaria s high absorption TurboCBD product, to evaluate its effects on
both cardiovascular health and cognitive function.
The study will have a double-blind and placebo controlled
cross-over design measuring effects both after a single dose, and also after 7
days of daily dosing in 24 volunteers. The study hypothesises that, following
TurboCBD supplementation, circulating CBD and nitric oxide will increase in
both young and old participants; that glucose and blood pressure will remain
stable; and that vascular function, and cognitive and physical exercise
performance will improve to a greater extent in older participants. This
research study has been approved by the Clinical Research Ethics Board at the
University of British Columbia ( UBC ).
Professor Philip Ainslie, PhD, Co-Director of the Centre for
Heart, Lung and Vascular Health, UBC Okanagan Campus, Kelowna, Canada, will be
Principal Investigator of a team of co-investigators. UBC has consistently been
ranked one of the top three universities in Canada, has over 62,000 students on
two campuses, and is further considered one of the top research universities in
the world. UBC has conducted several earlier studies in the cannabis sector,
available for review at https://news.ubc.ca/tag/marijuana/
This advanced study will utilize the latest clinical evaluation
techniques to provide pharma-level pharmacokinetic and pharmacodynamic
performance data of TurboCBD , including blood sampling, physiological measures,
cognitive function testing, vascular function testing, and exercise performance
testing. Outcome measurements will include circulating CBD and nitric oxide
markers, plasma glucose, plasma insulin, blood pressure, heart rate,
respiration, peripheral and brain blood flow and a battery of neuropsychological
Dr. Philip Ainslie comments that, This study gives us a great
opportunity to obtain world class clinical data on the health and performance
benefits of cannabidiol using Lexaria s unique high absorption TurboCBD
capsules in our state of the art laboratories. It is very exciting to be one of
the first if not the first to conduct these kinds of studies in Canada. The
potential implications of the study are far-reaching: from understanding the
fundamental biological mechanism(s) of high absorption CBD in humans, to how
this might influence blood vessel physiology and human performance. To quantify
the pharmacokinetics of TurboCBD will allow us to make informed recommendations
of optimum dosing in order to improve vascular health and performance throughout
healthy aging. Once we understand these processes better, the applications to
various clinical populations can then be explored. There are also many other CBD
products from Lexaria that could also be explored in due course the
partnership with academia and Lexaria Biosciences is an excellent means to
develop new collaborative ideas, products and positively impact society.
Lexaria is proud to be advancing our collective knowledge of
the benefits of CBD specifically showcasing the benefits of Lexaria s unique patented delivery
technology, said Chris Bunka, CEO of Lexaria Bioscience. Results will advance
Lexaria s ability to custom design products that increase the leading
performance our technology already offers to customers.
Additional information will be released upon completion and
interpretation of test results.
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive technology that promotes healthier ingestion
methods, lower overall dosing and higher effectiveness of lipophilic active
molecules. Lexaria has multiple patents pending in over 40 countries around the
world and was granted its first patents in the USA and in Australia related to
edible forms of cannabinoids. Lexaria s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules.
For regular updates, connect with Lexaria on Facebook (https://www.facebook.com/Lexaria-
Corp-106280556370600/) and Twitter (https://twitter.com/lexariacorp)
FOR FURTHER INFORMATION PLEASE CONTACT:
Alex Blanchard, Communications Manager
NetworkNewsWire (NNW)
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any of Lexaria s
postulated uses, benefits, or advantages for the patented and patent-pending
technology will in fact be realized in any manner or in any part. No statement
herein has been evaluated by the Food and Drug Administration (FDA). Lexaria